Related Experiment Video

Updated: May 7, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

ATP11B mediates platinum resistance in ovarian cancer

Myrthala Moreno-Smith1, J B Halder, Paul S Meltzer

  • 1Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

The Journal of Clinical Investigation
|April 16, 2013
PubMed

Insights

Researchers discovered ATP11B, a protein linked to cisplatin resistance in ovarian cancer. Inhibiting ATP11B may help overcome this resistance, improving platinum-based chemotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Platinum compounds are vital in treating solid tumors.
  • Cisplatin resistance, often due to altered platinum transport, limits therapeutic efficacy.
  • Understanding resistance mechanisms is crucial for improving cancer treatment.

Purpose of the Study:

  • To identify and characterize novel mechanisms of cisplatin resistance.
  • To investigate the role of ATP11B, a P-type ATPase, in cisplatin resistance.
  • To explore ATP11B as a potential therapeutic target for overcoming cisplatin resistance.

Main Methods:

  • Correlation analysis of ATP11B expression with tumor grade and cisplatin resistance in human ovarian cancer.
  • Assessment of cisplatin sensitivity following ATP11B gene silencing in ovarian cancer cell lines.
  • In vivo efficacy studies using combined cisplatin and ATP11B-targeted siRNA therapy in mouse models.
  • In vitro mechanistic studies on platinum content, efflux kinetics, and protein colocalization.

Main Results:

  • ATP11B expression positively correlated with ovarian tumor grade and cisplatin resistance.
  • ATP11B gene silencing resensitized resistant ovarian cancer cells to cisplatin.
  • Combined therapy demonstrated significant tumor growth inhibition in vivo.
  • ATP11B was found to enhance cisplatin export via vesicular transport.

Conclusions:

  • ATP11B plays a significant role in mediating cisplatin resistance in ovarian cancer.
  • Targeting ATP11B represents a promising strategy to enhance the effectiveness of platinum-based chemotherapy.
  • Inhibition of ATP11B could overcome resistance and improve patient outcomes in solid tumors treated with cisplatin.

More Related Videos

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...